| | Ephedrine Basic information |
| Product Name: | Ephedrine | | Synonyms: | alpha-(1-(methylamino)ethyl)-,(r-(r*,s*))-benzenemethano;alpha-(1-(methylamino)ethyl)benzenemethanol;alpha-[1-(methylamino)ethyl]-,[theta-(theta,s)]-benzenemethano;alpha-Hydroxy-beta-methyl amino propylbenzene;alpha-hydroxy-beta-methylaminepropylbenzene;alpha-hydroxy-beta-methylaminopropylbenzene;Benzenemethanol, alpha-[1-(methylamino)ethyl]-, [R-(R*,S*)]-;Biophedrin | | CAS: | 299-42-3 | | MF: | C10H15NO | | MW: | 165.24 | | EINECS: | 206-080-5 | | Product Categories: | Miscellaneous Natural Products;chiral;pharmaceutical intermediate | | Mol File: | 299-42-3.mol |  |
| | Ephedrine Chemical Properties |
| Melting point | 37-39 °C(lit.) | | Boiling point | 255 °C(lit.) | | alpha | -41 º (c=5, 1M HCl) | | density | 1.124 g/mL at 25 °C(lit.) | | refractive index | 1.4820 (estimate) | | Fp | 186 °F | | storage temp. | Refrigerator (+4°C) | | pka | pKa 8.02 (Uncertain);9.5 (Uncertain) | | optical activity | [α]21/D 41°, c = 5 in 1 M HCl | | Water Solubility | 47.62g/L(25 ºC) | | Merck | 13,3639 | | BRN | 2208730 | | Stability: | Stable. Combustible. Incompatible with strong acids, acid chlorides, acid anhydrides, strong oxidizing agents. May discolour in light. | | CAS DataBase Reference | 299-42-3(CAS DataBase Reference) | | NIST Chemistry Reference | Ephedrine(299-42-3) | | EPA Substance Registry System | Ephedrine (299-42-3) |
| | Ephedrine Usage And Synthesis |
| Description | Ephedrine is a naturally occurring alkaloid
drug (→Alkaloids) derived from Ephedra equistina
and Ephedra vulgaris. It can be prepared
synthetically. It is used mainly in combination
with other agents. | | Chemical Properties | white crystals or powder | | Originator | CAM,Rybar-UK | | Uses | Medicine (bronchodilator). | | Uses | Ephedrine, 1-phenyl-2-methylaminopropanol, C6H5 CH(OH)CH(NHCH3)CH3, is a white-to-colorless granular substance, unctuous (greasy) to the touch, and hygroscopic. The compound gradually decomposes upon exposure to light. Soluble in water, alcohol, ether, chloroform, and oils, and decomposes above this temperature. Ephedrine is isolated from stems or leaves of Ephedra, especially Ma huang (found in China and India). Medically, it is usually offered as the hydrochloride. In the treatment of bronchial asthma, ephedrine is known as a beta agonist. Compounds of this type reduce obstruction by activating the enzyme adenylate cyclase. This increases intracellular concentrations of cAMP (cyclic 3 5 -adenosine monophosphate) in bronchial smooth muscle and mast cells. Ephedrine is most useful for the treatment of mild asthma. In severe asthma, ephedrine rarely maintains completely normal airway dynamics over long periods. Ephedrine also has been used in the treatment of cerebral transient ischemic attacks, particularly with patients with vertabrobasilar artery insufficiency who have symptoms associated with relatively low blood pressure, or with postural changes in blood pressure. Ephedrine sulfate also has been used in drug therapy in connection with urticaria (hives). | | Definition | ChEBI: A phenethylamine alkaloid that is 2-phenylethanamine substituted by a methyl group at the amino nitrogen and a methyl and a hydroxy group at position 2 and 1 respectively. | | Definition | ephedrine: An alkaloid,C6H5CH(OH)CH(CH3)NHCH3 found inplants of the genus Ephedra, onceused as a bronchodilator in the treatmentof asthma. It is also used as astimulant and appetite suppressant.Structurally, it is a phenylethylamineand is similar to amphetamines, althoughless active. It is, however,widely used in the illegal synthesis ofmethamphetamine. The moleculehas two chiral centres. If the stereo- chemical conformations are opposite(i.e. 1R,2S or 1S,1R) the nameephedrine is used. If the conformationsare the same (1R,2R or 1S,2S)then the compound is called pseudoephedrine. | | Manufacturing Process | 120 grams of the fermentation product containing phenylpropanolone obtained
by extraction with ether (Biochemische Zeit-schrift Vol. 115, 1921, page 282
et seq.) are allowed to run, without further purification, in for about two hours
into a solution of 10 g of methylamine in 500 ml of ether in presence of 20 g
of activated aluminum, for example of the type described in British Patent No.
336,412, whilst stirring. Simultaneously 20-30 g of water are added,
dropwise. At once the vigorous reaction begins. It is moderated by periodical
cooling. Activated aluminum is aluminum, which has been amalgamated with
mercury. When it contacts with water, it liberates hydrogen and an insoluble
aluminum hydroxide is formed. Activated aluminum thus serves as the source
of hydrogen for the reaction. When the reaction is complete the ethereal
solution is filtered and the optically active base, which formed is extracted
from the filtrate by means of dilute acid. There is obtained the hydrochloride
of L-1-phenyl-2-methylamino-propanol-1 having a melting point of 214°C, and
having the optical rotation given in the literature. The yield amounts to 25-45
g of the hydrochloride depending upon the nature of the parent material.
360 g of ether extract phenylpropanolone used above as parent material are
distilled under reduced pressure. 300 grams of the fraction, which distils at
100-150°C/14 mm Hg are subjected to catalytic hydrogenation in presence of
colloidal platinum (70 ml of a 1% solution) and 85 grams of a 33% solution of
methylamine. It is advantageous to add some ether to the reaction mixture.
When absorption of hydrogen is complete, the ethereal solution is shaken with
hydrochloric acid and the L-phenyl-2-methylamino-propanol-1 is isolated from
the hydrochloric acid extract. The yield of the hydrochloride amounts to 110
grams. MP: 214°C.
100 g of L-1-phenylpropanol-1-one-2 isolated by the method of Neuberg
(Biochemische Zeitschrift Vol. 128, 1922, page 611) are dissolved in 200 ml of
ether, 75 g of a solution of methylamine (33%) are added and the whole is
shaken for about half an hour; condensation occurs with evolution of heat.
The reaction mixture is then treated with hydrogen in presence of 70 ml of a
1% colloidal solution of platinum. The reduction product was isolated as
hydrochloride. The hydrochloride of L-phenyl-2-methyl-amino-propanol-1
crystallizes from alcohol in the form of coarse prisms. MP: 214°-216°C. The
free base melts at 40°C. | | Brand name | Isofedrol (Boehringer Mannheim GmbH,
Germany). | | Therapeutic Function | Sympathomimetic; Bronchodilator | | Biological Functions | Ephedrine is a naturally occurring alkaloid that can cross
the blood-brain barrier and thus exert a strong CNS-stimulating
effect in addition to its peripheral actions.The latter
effects are primarily due to its indirect actions and depend
largely on the release of norepinephrine. However,
ephedrine may cause some direct receptor stimulation,
particularly in its bronchodilating effects. Because it resists
metabolism by both COMT and MAO, its duration
of action is longer than that of norepinephrine. As is the
case with all indirectly acting adrenomimetic amines, ephedrine is much less potent than norepinephrine; in
addition, tachyphylaxis develops to its peripheral actions.
Unlike epinephrine or norepinephrine, however, ephedrine
is effective when administered orally. | | Hazard | Toxic by ingestion. | | Mechanism of action | Ephedrine is a naturally occurring sympathomimetic amine that possesses
both direct (agonist at α- and β-receptors) and indirect activity via its
potentiation of noradrenaline release from sympathetic nerve terminals. It
causes an increase in HR, contractility, CO and arterial pressure (systolic >
diastolic). Bronchodilation occurs via a β2-mediated mechanism, and it is
occasionally used for this purpose. Its duration of action is longer than
endogenous catecholamines as it is not metabolised by COMT or MAO.
Tachyphylaxis can occur as a result of depletion of noradrenaline from nerve
terminals and persistent occupation of adrenergic receptors. Ephedrine
crosses the placenta and can increase fetal metabolic rate with a subsequent
metabolic acidosis. It is usually administered by i.v. bolus at a dose of 3–
9 mg. | | Pharmacology | Ephedrine increases systolic and diastolic blood
pressure; heart rate is generally not increased.
Contractile force of the heart and cardiac output are
both increased. Ephedrine produces bronchial smooth
muscle relaxation of prolonged duration when administered
orally. Aside from pupillary dilation, ephedrine
has little effect on the eye. | | Clinical Use | Ephedrine is useful in relieving bronchoconstriction
and mucosal congestion associated with bronchial
asthma, asthmatic bronchitis, chronic bronchitis, and
bronchial spasms. It is often used prophylactically to
prevent asthmatic attacks and is used as a nasal decongestant,
as a mydriatic, and in certain allergic disorders.
Although its bronchodilator action is weaker than that
of isoproterenol, its oral effectiveness and prolonged
duration of action make it valuable in the treatment of
these conditions. Because of their oral effectiveness and
greater bronchiolar selectivity, terbutaline and albuterol
are replacing ephedrine for bronchodilation. | | Side effects | Symptoms of overdose are related primarily to cardiac
and CNS effects. Tachycardia, premature systoles, insomnia, nervousness, nausea, vomiting, and emotional
disturbances may develop. Ephedrine should not be
used in patients with cardiac disease, hypertension, or
hyperthyroidism. | | Safety Profile | A human poison by an
unspecified route. An experimental poison
by intravenous, subcutaneous,
intramuscular, and intraperitoneal routes.
Moderately toxic by ingestion and parented
routes. Causes rapid pulse, rise in blood
pressure, and other actions similar to
epinephrine. An experimental teratogen.
Used in production of drugs of abuse. Has
been known to cause allergic sensitization.
When heated to decomposition it emits
toxic fumes of NOx. | | Purification Methods | Purify (-)-ephedrine by vacuum distillation (dehydrates) and forms waxy crystals or granules, and may pick up 0.5 H2O. The presence of H2O raises its melting point to 40o. [Moore & Taber J Amer Pharm Soc 24 211 1935.] The anhydrous base crystallises from dry ether [Fleming & Saunders J Chem Soc 4150 1955]. It gradually decomposes on exposure to light and is best stored in an inert atmosphere in the dark (preferably at -20o). Its solubility in H2O is 5%, in EtOH it is 1% and it is soluble in CHCl3, Et2O and mineral oils. It has pKa values in H2O of 10.25 (0o) and 8.69 (60o) [Everett & Hyne J Chem Soc 1136 1958, Prelog & H.flinger Helv Chim Acta 33 2021 1950] and pK a 8.84 in 80% aqueous methoxyethanol [Simon Helv Chim Acta 41 1835 1958]. The hydrochloride has m 220o (from EtOH/Et2O) and [] D20 -38.8o (c 2, EtOH). [IR: Chatten & Levi Anal Chem 31 1581 1959.] The anhydrous base crystallises from Et2O [Fleming & Saunders J Chem Soc 4150 1955]. [Beilstein 13 H 373, 13, III 1720, 13 IV 1879.] |
| | Ephedrine Preparation Products And Raw materials |
|